Background: Clostridium difficile infection (CDI) is related to the use of antibiotics and ranges in severity from mild diarrhea to pseudomembranous colitis and death. A new strain of C. difficile (polymerase chain reaction ribotype 027) has been associated with increased severity of CDI and outbreaks but is still uncommon in New Zealand or Australia. The mortality related to CDI in the Canterbury District Health Board region is unknown.Methods: This was a case-control study. Cases (167) were all patients testing positive for C. difficile toxins A and B during 2009/2010 in the DHB's hospitals. Two control subjects (334) testing negative were selected from the same database as the cases and matched for age, sex, and admission to the same medical specialty. Potential predictors of complications such as mortality before 30 days were assessed.Results: The median age was 73 years (range, 1Y99 years). Overall 30-day mortality was 17% for the cases and 9% for the control subjects (P G 0.01). Males had an increased mortality (P G 0.01). Mortality was increased in untreated cases (P G 0.01) and cases with white blood cell (WBC) count outside the reference range (P G 0.01).Conclusions: Even in hospitals with a low CDI rate, there might be significant mortality in the older age group, with an increased risk of mortality in males and patients not treated for CDI.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.